By contrast, in pancreatic cancer - where ARID1A mutations and loss of expression are also common [53] - in vitro knockdown led to divergent effects depending on the cell type used, including reduced cell proliferation [54] as shown here for RT112 cells. Here, ARID1A is linked to pancreatic neoplasm.